New-onset atrial fibrillation predicts heart failure progression.
暂无分享,去创建一个
[1] S. Liggett,et al. Race, common genetic variation, and therapeutic response disparities in heart failure. , 2014, JACC. Heart failure.
[2] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[3] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[4] C. O'connor,et al. Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism. , 2013, JACC. Heart failure.
[5] Richard B Devereux,et al. Relationship of Sudden Cardiac Death to New-Onset Atrial Fibrillation in Hypertensive Patients With Left Ventricular Hypertrophy , 2013, Circulation. Arrhythmia and electrophysiology.
[6] C. O'connor,et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation , 2013, European journal of heart failure.
[7] Elsayed Z Soliman,et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. , 2013, JAMA internal medicine.
[8] I. V. Van Gelder,et al. The importance of whether atrial fibrillation or heart failure develops first , 2012, European journal of heart failure.
[9] V. Roger,et al. Atrial Fibrillation and Mortality in Heart Failure: A Community Study , 2011, Circulation. Heart failure.
[10] L. Køber,et al. Incidence of Atrial Fibrillation in Patients with either Heart Failure or Acute Myocardial Infarction and Left Ventricular Dysfunction: A Cohort Study , 2011, BMC cardiovascular disorders.
[11] C. O'connor,et al. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST]). , 2010, American heart journal.
[12] W. Stevenson,et al. Atrial Fibrillation in Congestive Heart Failure , 2010, Cardiology in review.
[13] J. McMurray,et al. The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature‐based meta‐analysis , 2009, European journal of heart failure.
[14] W. Aronow,et al. A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. , 2009, European heart journal.
[15] S. Liggett,et al. Determination of Hospitalization Type by Investigator Case Report Form or Adjudication Committee in a Large Heart Failure Clinical Trial (BEST) , 2008 .
[16] L. Køber,et al. Atrial fibrillation, ischaemic heart disease, and the risk of death in patients with heart failure. , 2006, European heart journal.
[17] D. J. Veldhuisen,et al. Presence and development of atrial fibrillation in chronic heart failure , 2006, European journal of heart failure.
[18] A. Moss,et al. Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. , 2006, Heart rhythm.
[19] Douglas L Mann,et al. Mechanisms and models in heart failure: the biomechanical model and beyond. , 2005, Circulation.
[20] M. Domanski,et al. Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the &bgr;-Blocker Evaluation of Survival Trial , 2004, Circulation.
[21] A. John Camm,et al. Atrial fibrillation and heart failure: natural history and pharmacological treatment. , 2004, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[22] G. L’italien,et al. The expanding national burden of heart failure in the United States: the influence of heart failure in women. , 2004, American heart journal.
[23] M. Domanski,et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. , 2003, Journal of the American College of Cardiology.
[24] J. Murabito,et al. Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study , 2003, Circulation.
[25] M. Domanski,et al. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.
[26] T. R. I. Nvestigators. A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE , 2001 .
[27] M A Waclawiw,et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. , 1998, Journal of the American College of Cardiology.
[28] L. Tavazzi,et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. , 1998, Journal of the American College of Cardiology.
[29] R. Coleman,et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. , 1986, The American journal of cardiology.